Theravance Biopharma, Inc. (NASDAQ:TBPH) Q2 2025 Earnings Call Transcript
Operator: Ladies and gentlemen, good afternoon. I'd like to welcome everyone to the Theravance Biopharma Second Quarter 2025 Conference Call.
Theravance Biopharma Inc. (TBPH)
Market is closed
Sector: Healthcare
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Madison Avenue Partners Eli Samaha | 9,511,150 | $104,907,985 | 7% | |
| 2. | Weiss Asset Management Andrew Weiss | 7,457,060 | $82,251,372 | 0.95% | |
| 3. | Newtyn Management Noah Levy And Eugene Dozortsev | 4,950,000 | $54,598,500 | +5% | 8.27% |
| 4. | Irenic Capital Management Adam Katz And Andy Dodge | 2,760,948 | $30,453,256 | 4.49% | |
| 5. | Park West Asset Management Peter S. Park | 1,799,081 | $19,843,863 | -1% | 1.5% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $7.80 | 999,800 | $7,798,440.00 | 9,511,150 | 2024-08-07 | Filing | |
| $8.75 | 499,324 | $4,369,085.00 | 8,511,350 | 2024-05-01 | Filing | |
| $8.75 | 999,800 | $8,748,250.00 | 8,012,026 | 2024-05-01 | Filing | |
| $22.54 | 1,000 | $22,540.00 | 56,757 | 2018-05-21 | Filing | |
| $26.34 | 4,000 | $105,358.80 | 213,180 | 2017-08-21 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $11.39 | 4,000 | $45,551.60 | 326,918 | 2025-07-14 | Filing | |
| $11.39 | 5,318 | $60,548.09 | 330,918 | 2025-07-14 | Filing | |
| $11.39 | 682 | $7,769.82 | 336,236 | 2025-07-14 | Filing | |
| $11.00 | 24,000 | $264,000.00 | 336,918 | 2025-06-02 | Filing | |
| $9.00 | 4,000 | $36,000.00 | 370,038 | 2025-04-21 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 414,715 | $6,054,839 | 0.01% | |
| 2. | 181,477 | $2,649,564 | 0.01% | |
| 3. | 73,556 | $1,073,918 | 0.1% | |
| 4. | 52,617 | $768,208 | 0.06% | |
| 5. | 44,100 | $643,860 | 0% |
News See All
Viatris Gains China Approval for COPD Drug Yupelri, Triggers $7.5M Payment to Theravance BioPharma
Viatris Inc. (NASDAQ:VTRS) is one of the best low priced pharma stocks to buy now.
Theravance Biopharma, Inc. (NASDAQ:TBPH) Q1 2025 Earnings Call Transcript
Operator: Hello, ladies and gentlemen. Good afternoon. I would like to welcome everyone to the Theravance Biopharma First Quarter 2025 Conference Call.
Theravance Biopharma, Inc. (NASDAQ:TBPH) Q4 2024 Earnings Call Transcript
Theravance Biopharma, Inc. (NASDAQ:TBPH) Q4 2024 Earnings Call Transcript February 26, 2025Theravance Biopharma, Inc. misses on earnings expectations.
Theravance Biopharma, Inc. (NASDAQ:TBPH) Q3 2024 Earnings Call Transcript
Operator: Ladies and gentlemen, good afternoon. I would like to welcome everyone to the Theravance Biopharma Third Quarter 2024 Conference Call.
Theravance Biopharma, Inc. (NASDAQ:TBPH) Q2 2024 Earnings Call Transcript
Theravance Biopharma, Inc. (NASDAQ:TBPH) Q2 2024 Earnings Call Transcript August 5, 2024Theravance Biopharma, Inc. misses on earnings expectations.
Theravance Biopharma, Inc. (NASDAQ:TBPH) Q1 2024 Earnings Call Transcript
Operator: Ladies and gentlemen, good afternoon. I'd like to welcome everyone to the Theravance Biopharma First Quarter 2024 Conference Call.
Theravance Biopharma, Inc. (NASDAQ:TBPH) Q4 2023 Earnings Call Transcript
Theravance Biopharma, Inc. beats earnings expectations. Reported EPS is $0.03, expectations were $-0.04.
Billionaire Seth Klarman’s Biotech Stock Picks
In this article, we discuss billionaire Seth Klarman’s biotech stock picks.
Theravance Biopharma, Inc. (NASDAQ:TBPH) Q3 2023 Earnings Call Transcript
Operator: Ladies and gentlemen, good afternoon. I'd like to welcome everyone to Theravance Biopharma's Third Quarter 2023 Conference Call.
Hedge Fund Resource Center Billionaire Hedge Funds
